[go: up one dir, main page]

WO2013013268A1 - Dosages d'évaluation de plaquettes, diagnostic et kits associés - Google Patents

Dosages d'évaluation de plaquettes, diagnostic et kits associés Download PDF

Info

Publication number
WO2013013268A1
WO2013013268A1 PCT/AU2012/000883 AU2012000883W WO2013013268A1 WO 2013013268 A1 WO2013013268 A1 WO 2013013268A1 AU 2012000883 W AU2012000883 W AU 2012000883W WO 2013013268 A1 WO2013013268 A1 WO 2013013268A1
Authority
WO
WIPO (PCT)
Prior art keywords
platelets
pmr
test
relationship
assay
Prior art date
Application number
PCT/AU2012/000883
Other languages
English (en)
Inventor
Elizabeth GARDINER
Robert Andrews
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University filed Critical Monash University
Publication of WO2013013268A1 publication Critical patent/WO2013013268A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders

Definitions

  • This invention relates generally to assays and kits for assessing or monitoring the proteolytic state of platelets in blood , samples, such as whole blood or fractions thereof, from a subject.
  • the present invention enables assays useful in diagnosis, prognosis, monitoring, treatment or stratification of a human or non-human mammalian subject with respect to thrombocytopenia or conditions associated with thrombocytopenia.
  • the present invention has practical uses, inter alia, in the treatment and management of thrombocytopenia and may be used in existing or newly developed knowledge-based architecture or platforms associated with pathology services.
  • Platelets are small, anuclear fragments of megakaryocytes that circulate in the blood and make essential contributions to functions such as blood clotting and wound healing. They play a central role in cardiovascular disease, blood homeostasis, inflammation and tumor metastasis. They are produced by megakaryocytes which are large, polyploid cells that deve lop in the bone marrow and spleen . Megakaryocytes release platelets into the blood stream where, in humans, they circulate for around 7 to 10 days where they may take part in a haemostatic process or proceed to destruction by the reticuloendothelial system, primarily in the liver and spleen.
  • thrombocytopenia low platelet count
  • thrombocytopenia is a common problem in the clinic, particularly in haematological and oncological practice, and leads to potentially fatal haemorrhagic episodes. It can occur congenitally, and a number of inherited disorders having been defined, but the majority of thrombocytopenias seen in the clinic are the result of other causes. It can be a major problem for patients undergoing cancer chemotherapy. Acute episodes of cytotoxic drug-related thrombocytopenia, in addition to putting the patient at immediate risk, can force dose modifications or treatment withdrawal.
  • thrombocytopenia is also frequently encountered in myelodysplasia syndromes (MDS), idiopathic thrombocytopenia purpura (ITP), antiphospholipid antibody syndrome (APS) and thrombotic thrombocytopenia purpura (TTP), and chronic liver disease, and is also associated with viral infections, particularly AIDS and bacterial infection and sepsis. In these more chronic contexts, thrombocytopenia may result from defective platelet production through bone marrow defects, or elevated platelet destruction often as the result of autoimmune reactions.
  • Treatment for low platelet numbers includes platelet transfusion for subjects with bone marrow defects, and steroid therapy where immune mediated destruction of platelets is indicated, both of which are only short term solutions and carry significant clinical risks.
  • Platelet transfusion for example, can give rise to immunohaematological side-effects and risk of infection which can be associated with morbidity and mortality. If autoimmune mediated thrombocytopenia is misdiagnosed, patients can be exposed to high levels of steroids or immunosuppressants that will not treat the thrombocytopenia and are likely to provoke significant unwanted side effects.
  • Current methods of distinguishing between thrombocytopenia caused by platelet destruction and thrombocytopenia caused by reduced platelet production involve invasive and time consuming bone marrow biopsy.
  • [0007J Receptors spanning the platelet membrane such as the von Willebrand factor receptor GP (glycoprotein) Ib-IX-V complex and GPVI that binds collagen form a unique adheso-signaling complex which acts synergistically to initiate platelet adhesion, activation and integrin dependent aggregation in haemostasis and thrombosis (Gardiner et ah, Journal of Thrombosis and Haemostasis 5: 1530-1537, 2007 incorporated herein in its entirety by reference).
  • GP von Willebrand factor receptor GP
  • GPIb is a heterodimeric transmembrane protein.
  • the receptor comprises a large GPlba chain disulfide linked to a smaller GPIbp chain.
  • the a-chain comprises an N-terminal ectodomain and a C-terminal cytoplasmic domain.
  • Ectodomain shedding is mediated by metalloproteinases which cleave the ectodomain close (proximal) to the platelet membrane.
  • ectodomain portions of GPV and GPVI are also shed.
  • the residual portion of GPlba that is retained after shedding, is associated with the platelet membrane and is disulfide linked to GPIbp.
  • the residual portion comprises a small, unshed ectodomain portion N-terminal to the G465V cleavage site and a cytoplasmic portion domain C-terminal to the G465V cleavage site.
  • the present invention enables assays for evaluating the proteolytic status of platelets by assessing the proteolytic status of a shed platelet membrane receptor (referred to herein as "PMR") including one of GPlba, GPV and GPVI. »n
  • PMR shed platelet membrane receptor
  • Some aspects of the method are predicated, in part, upon the determination by the inventors that a measure of the proportion of intact receptor out of the total amount of receptor, whether intact or cleaved, provides an improved and informative assessment of platelet state in healthy and thrombocytopenic subjects.
  • a statistically significant reduction in intact GPlba relative to total GPlba was observed in subjects with idiopathic thrombocytopenia (ITP), antiphospholipid antibody syndrome (APS) and thrombotic thrombocytopenia purpura (TTP), compared to healthy controls.
  • ITP idiopathic thrombocytopenia
  • APS antiphospholipid antibody syndrome
  • TTP thrombotic thrombocytopenia purpura
  • the assay indicated an increased shedding of the GPlba ectodomain of GPlba that was independent of platelet numbers.
  • the measured levels of platelet bound GPlba ectodomain alone or the levels of the cytoplasmic domain of GPlba alone were uninformative in this respect.
  • the proteolytic state of GPlba and at least one of GPV and GPVI is assessed.
  • the thrombocytopenic subjects had a form of thrombocytopenia which is associated with supernormal peripheral platelet destruction.
  • a high ratio or range of ratios e.g., 0.9-1.0 or 0.85-1.0 (arbitrary values) of intact to total GPlba was found in healthy subjects.
  • a lower ratio or range of ratios such as 0.8 and below or 0.85 and below, was found in samples subjected to cleavage agents or in subjects with thrombocytopenias characterized by elevated platelet clearance. Thresholds can be determined by the skilled addressee using recognized procedures.
  • Proteolytic state of platelets is determined in the assays as a measure of the proportion of platelets in a sample that have an intact PMR or a measure of this proportion of PMR that is intact out of the total number of detected receptors.
  • Healthy subjects for example, those subjects not exhibiting thrombocytopenia
  • Thrombocytopenic subjects have low levels of platelets but if their thrombocytopenia is due to bone marrow deficits then the platelets in circulation or stored are not characterised by supernormal levels of cleaved PMR as determined herein.
  • subjects with increased levels of platelet clearance exhibit increased levels of PMR cleavage.
  • Their proportion of intact to total PMR is reduced to less than 90%, less than 85%, less than 80%, less than 75%, or even less than 70% in some subjects. This proportion is expressed as a test relationship and compared to a control or a corresponding reference relationship to determine the significance of the test value obtained.
  • diagnostic threshold values are obtained by analysis of large numbers of test and reference subjects and illustrative values are provided herein.
  • the present assays provide a significant advance over less informative prior art methods of non-invasively assessing platelets and thrombocytopenia.
  • the present assays permit qualitative and quantitative assessments of proteolytic status of platelets which are independent of the platelet number and independent of GPlba surface levels. This may be used to assess whether a subject has thrombocytopenia as a result of elevated platelet clearance or as a result of decreased platelet production.
  • the present assay provides an early indication of a subject's response to treatment for thrombocytopenia.
  • the subject assays facilitate stratification of thrombocytopenia as thrombocytopenia including defects in platelet production and/or thrombocytopenia including altered platelet function such as enhanced platelet activation/destruction/clearance.
  • the invention has been illustrated using the human GPIba platelet receptor as an exemplary PMR, the skilled person will appreciate that other similar cleaved platelet receptors may be assayed using the same approach to provide useful information concerning the proteolytic cleavage state of platelets.
  • the proteolytic state of GPIba and at least one of GPV and GPVI is assessed.
  • ITP, APS and TTP are illustrative examples of conditions associated with elevated levels of platelet clearance, however any such condition is encompassed.
  • the present invention enables an assay for assessing the proteolytic state of test platelets in a biological sample.
  • the assays comprise detecting the level of intact platelet membrane receptor (PMR) associated with platelets (a), and the level of total (cleaved and uncleaved) PMR (b) associated with platelets in the sample, and comparing a ratio or other measure of the relationship between levels (a) and (b) (a "test relationship") to a corresponding ratio or relationship measure derived from at least one reference biological sample (a "reference relationship”) selected from a sample obtained from one or more normal (e.g.
  • PMR platelet membrane receptor
  • normal reference relationship or from one or more reference samples having predetermined levels of intact and total PMR indicating that the reference sample has supernormal levels of cleaved PMR associated with platelets
  • supernormal cleavage reference relationship indicates the proteolytic state of platelets in the test sample
  • a similarity between the test relationship and the normal reference relationship or a difference between the test relationship and the supernormal cleavage reference relationship indicates the absence of supernormal levels of proteolytic cleavage in test platelets.
  • a similarity between the test relationship and the supernormal cleavage reference relationship or a difference between the test relationship and the normal reference relationship indicates the presence of supernormal levels of proteolytic cleavage in test platelets.
  • the assay comprises (i) contacting test platelets with an agent capable of permeabilizing platelets. This permeabilization step is used when the PMR antigen binding molecule that binds the residual domain of the PMR, binds to a cytoplasmic region of the residual domain.
  • the assays comprise (i) or (ii) contacting test platelets with a PMR antigen-binding molecule that binds to the ectodomain (that extracellular portion of the PMR which is shed from the surface of the platelet after cleavage of the receptor ("shed") close to the platelet membrane) of PMR on the surface of platelets to provide a measure of the level of intact PMR receptor; (iii) contacting test platelets with a PMR antigen-binding molecule that binds to the residual domain (that portion of the receptor retained after ectodomain shedding) of PMR associated with platelets after ectodomain cleavage to provide a measure of the level of total (cleaved and uncleaved) PMR receptor ("total”); (iv) comparing a ratio or other measure of the relationship between the measured level in (ii) and (iii) ("test relationship”) to a corresponding relationship measure from at least one reference sample (“reference relationship”) selected from a sample
  • the antigen- binding molecule that binds to the residual domain binds to the cytoplasmic domain of PMR.
  • platelets are permeabilized with, for example, a mild detergent to allow intracellular access of antibodies to the cytoplasmic domain, if required.
  • the antigen binding molecule is/are labeled with a detectable substance.
  • a similarity between the test relationship and the normal reference relationship or a difference between the test relationship and the supernormal cleavage reference relationship indicates the absence of supernormal levels of proteolytic cleavage in test platelets
  • a similarity between the test relationship and the supernormal cleavage reference relationship or a difference between the test relationship and the normal reference relationship indicate the presence of supernormal levels of proteolytic cleavage in test platelets.
  • the test platelets are stored platelets, such as platelets in stored blood or stored platelet concentrates.
  • the biological sample is whole blood.
  • blood is fractioned or processed to remove one or more cellular components other than platelets.
  • the assay further comprises contacting platelets with an RNA-staining molecule and measuring the level of RNA in test platelets as an indication of platelet age.
  • the PMR receptor is GPIba.
  • the ectodomain is N-terminal to G465V or the equivalent amino acid in a homolog of GPIba.
  • the residual domain of GPIba is C-terminal to G465V or the equivalent amino acid in a GPIba homolog.
  • the PMR receptor is GPV.
  • the ectodomain is N-terminal to P494V or the equivalent amino acid in a GPV homolog.
  • the residual domain of GPV is C-terminal to P494V or the equivalent amino acid in a GPVI homolog.
  • the PMR receptor is GPVI.
  • the ectodomain is N-terminal to P243Q or the equivalent amino acid in a GPVI homolog.
  • the residual domain of GPVI is C-terminal to P243Q or the equivalent amino acid in a GPVl homolog.
  • the subject assay is provided for use in the diagnosis, prognosis, monitoring, treatment or management of conditions associated with thrombocytopenia or for use in the management of stored blood products.
  • the assay is suitable for and employs flow cytometry as the detection system.
  • the antigen binding molecule that binds to the ectodomain of PMR on the surface of platelets is labelled with a first fluorescent or other detectable molecule
  • the antigen binding molecule that binds to the residual domain of PMR receptor associated with platelets after receptor cleavage is labelled with a second fluorescent or other detectable molecule.
  • test platelets are subjected to flow cytometry to detect and provide a measure of the level of intact PMR receptor or proportion of platelets with intact PMR receptor ("intact”) and to detect and provide a measure of the level of total (cleaved and uncleaved) PMR receptor or the proportion of platelets with cleaved and uncleaved PMR receptor ("total").
  • the present invention provides a flow cytometric assay for assessing the proteolytic state of test platelets in a biological sample, the assay comprising (i) contacting test platelets with an agent capable of permeabilizing platelets, (ii) contacting test platelets with a PMR antigen-binding molecule that binds to the ectodomain of PMR on the surface of platelets wherein the antigen binding molecule is labelled with a first fluorescent or other detectable molecule to provide a measure of the level of "intact" PMR receptor; (iii) contacting test platelets with a PMR antigen- binding molecule that binds to the residual domain of PMR associated with platelets after ectodomain cleavage and wherein the antigen-binding molecule is labelled with a second fluorescent or other detectable molecule to provide a measure of the level of total (cleaved and uncleaved) PMR receptors ("total”); (iv) subjecting labelled test
  • test relationship a measure of the relationship between the detected levels in (ii) and (iii) ("test relationship") to a corresponding measure of the relationship between the detected levels in (ii) and (iii) from at least one reference sample ("reference relationship") selected from a sample obtained from one or more normal (e.g. healthy or non-thrombocytopenic) reference subjects ("normal reference relationship”) or from one or more reference subjects having predetermined detected levels of intact and total PMR indicating that the reference subject has supernormal measured levels of cleaved PMR associated with platelets (“supernormal cleavage reference relationship”), wherein the similarity or difference between the test and reference relationships indicates the proteolytic state of platelets in the test sample.
  • normal reference relationship normal (e.g. healthy or non-thrombocytopenic) reference subjects
  • supernormal cleavage reference relationship a measure of the relationship between the test and reference relationships indicates the proteolytic state of platelets in the test sample.
  • each PMR may have one or more unique detectable molecules.
  • the assays further comprise contacting platelets with an RNA-staining fluorescent molecule and measuring the level of RNA in test platelets.
  • test and reference relationships are compared for two or more PMR.
  • the antigen binding molecules and/or assays of the present invention may be provided in kit format.
  • the invention provides a kit for assessing the proteolytic state of test platelets in a biological sample, the kit comprising: (i) a PMR antigen-binding molecule that binds to the ectodomain of PMR, wherein the antigen- binding molecule is either immobilized (bound) to one or more test portions and/or contained within a conjugate portion; and/or (ii) a PMR antigen-binding molecule that binds to the residual domain of PMR associated with platelets after ectodomain cleavage, wherein the antigen-binding molecule is either immobilized (bound) to one or more test portions and/or contained within a conjugate portion and (iii) instructions for using the device for assessing the proteolytic status of platelets.
  • the PMR receptor is GPIba.
  • the PMR receptor is GPV.
  • the PMR receptor is GPVI.
  • the GPIba is assessed together with one or two of GPV and GPVI.
  • the invention provides a kit as described herein for use in the diagnosis, prognosis, monitoring, treatment or management of conditions associated with thrombocytopenia or for use in the management of stored blood products.
  • the PMR is GPV.
  • the PMR is GPVI.
  • the PMR is GPIba and the assay further comprises each step wherein the PMR is GPV and/or further comprises each step wherein the PMR is GPVI.
  • the assay comprises detecting (a) and (b) to establish a test relationship for GPIba, GPV and GPVI and determining a reference relationship for GPIba, GPV and GPVI.
  • the present invention contemplates an antigen- binding molecule that is immuno-interactive with the residual domain of GPIba associated with the platelet after proteolytic cleavage and shedding of the ectodomain.
  • the invention provides and an antigen-binding molecule that is immuno-interactive with the ectodomain or residual domain of PMR for use in the assays of the present invention.
  • the present invention provides a solid or semi-solid support comprising at least one antigen-binding molecule that specifically binds to the ectodomain or residual domain of one or more PMR as, broadly described herein, immobilized thereon.
  • the solid or semi-solid assays comprise a spatial array of antigen-binding molecule immobilized thereon suitable for detecting ratios of intact:total PMR.
  • the assays of the present invention distinguish between forms of thrombocytopenia characterized by platelet destruction such as immune mediated thrombocytopenias, where the ratio or value (test relationship) of intact to total GPIba in circulating platelets indicates whether thrombocytopenia results substantially from platelet destruction or substantially from reduced platelet production. Accordingly, in one embodiment, the present assays are useful for stratifying subjects in distinguishing between (i) thrombocytopenia associated with increased clearance in particular immune mediated thrombocytopenias, and (ii) bone-marrow deficiencies resulting in thrombocytopenia, and thus in the management, treatment or prophylaxis of thrombocytopenia.
  • the present invention relates to a method of treatment or prophylaxis of a subject comprising assessing a test sample from the subject for platelet state as described herein and then providing at least one therapy to the subject or conducting further tests and therapies depending upon the results of the assay.
  • therapies include steroid, anti-inflammatory or immunoglobulin therapy, platelet transfusion, plasma exchange, as appropriate.
  • the assays comprise (i) detecting (a or ta) the level of an intact PMR and detecting (b or tb) the level of total (cleaved or uncleaved) PMR associated with platelets in a test biological sample.
  • the methods comprise (ii) comparing a measure of the relationship between levels (a) and (b) (the "test" relationship) to a control.
  • the test relationship is ta tb.
  • the PMR is GPIba.
  • the methods further comprise comparing a measure of the relationship between levels (a) and (b) from the test sample to a corresponding measure of the relationship between levels (a or ra) and (b or rb) derived from a reference biological sample (the "reference" relationship e.g., ra/rb).
  • a measure of the relationship between levels (a) and (b) from the test sample to a corresponding measure of the relationship between levels (a or ra) and (b or rb) derived from a reference biological sample (the "reference" relationship e.g., ra/rb).
  • subjects receive different treatment regimes and/or monitoring regimes based upon the proteolytic state of the platelets determined using the test relationship.
  • subjects identified as having an elevated level of PMR cleavage/shedding may receive an appropriate steroid therapy.
  • step (ii) comprises comparing a measure of the relationship between levels (a) and (b) ("test relationship") to a corresponding relationship measure derived from at least one reference biological sample (“reference relationship") selected from a sample obtained from one or more normal (e.g. healthy) reference subjects ("normal reference relationship”) or from one or more reference samples having predetermined measured levels of intact and total PMR indicating that the reference subject has supernormal measured levels of cleaved PMR associated with platelets (“supernormal cleavage reference relationship”), wherein the similarity or difference between the test relationship and the reference relationship indicates the proteolytic state of platelets in the test sample.
  • test relationship a measure of the relationship between levels (a) and (b)
  • reference relationship a corresponding relationship measure derived from at least one reference biological sample
  • normal reference relationship selected from a sample obtained from one or more normal (e.g. healthy) reference subjects
  • normal reference relationship normal reference relationship
  • reference samples having predetermined measured levels of intact and total PMR indicating that the reference subject has supernormal measured levels of cle
  • the assay comprises (i) contacting test platelets with an agent capable of permeabilizing platelets, (ii) contacting test platelets with a PMR antigen-binding molecule that binds to the ectodomain of PMR on the surface of platelets to provide a measure of the level of intact PMR; (iii) contacting test platelets with a PMR antigen-binding molecule that binds to the residual domain of PMR associated with platelets after ectodomain cleavage to provide a measure of the level of total (cleaved and uncleaved) PMR ("total”); (iv) comparing a measure of the relationship between the measured levels in (ii) and (iii) ("test relationship”) to a corresponding relationship measure from at least one reference sample (“reference relationship”) selected from a sample obtained from one or more normal (e.g.
  • normal reference relationship or from one or more reference subjects having predetermined measured levels of intact and total PMR indicating that the reference subject has supernormal measured levels of cleaved PMR associated with platelets (“supernormal cleavage reference relationship”), wherein the similarity or difference between the test and reference relationships indicates the proteolytic state of platelets in the test sample.
  • a similarity between the test relationship and the normal reference relationship or a difference between the test relationship and the supernormal cleavage reference relationship indicates the absence of supernormal levels of proteolytic cleavage in test platelets, and wherein a similarity between the test relationship and the supernormal cleavage reference relationship or a difference between the test relationship and the normal reference relationship indicate the presence of supernormal levels of proteolytic cleavage in test platelets.
  • the biological sample is whole blood.
  • the assays further comprise contacting platelets with an RNA-staining molecule and measuring the level of RNA in test platelets.
  • the PMR is GPIba.
  • the PMR is GPIba and the assay further comprises steps wherein the PMR is GPV and/or wherein the PMR is GPVI.
  • the antigen binding molecule that binds to the ectodomain of PMR on the surface of platelets is labelled with a first fluorescent or other detectable molecule, wherein the antigen binding molecule that binds to the residual domain of PMR associated with platelets after receptor cleavage is labelled with a second fluorescent or other detectable molecule, and wherein test platelets are subjected to flow cytometry to provide a measure of the level of intact PMR or proportion of platelets with intact PMR ("intact") and a measure of the level of total (cleaved and uncleaved) PMR or the proportion of platelets with cleaved and uncleaved PMR ("total").
  • subjects identified as having an elevated bend of PMR cleavage may receive an appropriate steroid therapy.
  • the invention enables an assay to monitor the response of a thrombocytopenic subject to therapy such as steroid or antiinflammatory therapies.
  • a test relationship in this case GPIba intac total ratio provided an early marker of platelet status and platelet recovery during treatment. Accordingly, the subject assays are useful for indicating whether further similar treatment is warranted or that a different treatment such as platelet transfusion is warranted.
  • the assays facilitate the identification of appropriate treatment protocols and are also instructive in pharmacotranslational studies and in the clinical management of patients.
  • the present assay may be used to guide drug discovery and testing for agents that modulate platelet survival, production or clearance, or platelet function in a subject or blood product, as appropriate.
  • Figure 1 is a pictorial representation of a flow cytometry assay to assess the level of intact GPIba (red fluorochrome) and total GPIba (green fluorochrome) in a. circulating platelet population.
  • the ratio of red to green fluorescence reflects the proteolytic status of GPIba, and therefore platelet age and extent of platelet activation and destruction.
  • Figure 2 is a pictorial representation of platelet membrane receptors GPIba, GPV and GPVI which undergo shedding in vivo.
  • the cleavage sites for each shed receptor have been identified in humans and antibodies or other antigen binding molecules are routinely generated against shed ectodomain or residual (cytoplasmic) domains (see Shen et al, Blood 95: 903-910, 2000; Gardiner et al, 2007 (supra)).
  • Figure 3 is a graphical representation of technical data showing that GPIba intac total ratio is a marker for ITP thrombocytopenia and further provides an early marker for platelet recovery during steroid or other therapy.
  • Figure 4 is a graphical representation of data showing the temporal relationship between GPIba index (Intact/Total) and platelet count in ITP-C subject shown to be responsive to steroids after one month.
  • Figure 5 is a graphical representation of data showing the temporal relationship between GPIba index (Intact/Total) and platelet count in ITP-X subject non responsive to steroids, treated with azathioprine at arrow.
  • Figure 6 is a graphical representation of data showing the temporal relationship between GPIba index (Intact/Total) and platelet count in ITP-V subject treated with thrombopoietin (TPO) mimic, Romip!ostim.
  • GPIba index Intact/Total
  • TPO thrombopoietin
  • Figure 7 is a graphical representation of data showing the temporal relationship between GPIba index (IntactAOtal) and platelet count in ITP-J subject treated with steroids, then the TPO mimic Romiplostim at arrow.
  • antigen-binding molecule is meant a molecule that has binding affinity for a target antigen.
  • the target antigen is a PMR, including the shed ectodomain portion thereof or the residual (including cytoplasmic) portion thereof as described elsewhere herein. It will be understood that this term extends to immunoglobulins, immunoglobulin fragments and non-immunoglobulin derived protein or protein frameworks that exhibit antigen-binding activity.
  • e immunoglobulins, immunoglobulin fragments and non-immunoglobulin derived protein or protein frameworks that exhibit antigen-binding activity.
  • an antigen-binding molecule refers to a binding reaction which is determinative of the presence of an antigen in the presence of a heterogeneous population of proteins and other biologies.
  • the specified antigen-binding molecules bind to a particular antigen and do not bind in a significant amount to other proteins or antigens present in the sample.
  • Specific binding to an antigen under such conditions may require a antigen-binding molecule that is selected for its specificity for a particular antigen.
  • antigen-binding molecules can be raised to a selected protein antigen, which bind to that antigen but not to other proteins present in a sample.
  • immunoassay formats may be used to select antigen-binding molecules specifically immuno-interactive with a particular protein.
  • solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immuno-interactive with a protein. See Harlow and Lane, "Antibodies, A Laboratory Manual", Cold Spring Harbor Publications, New York, 1988 for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.
  • Reference herein to "immuno-interactive” includes reference to any interaction, reaction, or other form of association between molecules and in particular where one of the molecules is, or mimics, a component of the immune system.
  • biological sample refers to a sample comprising platelets that may be extracted, substantially untreated (anticoagulant may be present), diluted or concentrated or derived from a subject.
  • the sample includes a biological fluid containing platelets such as, without limitation, whole blood or fraction thereof including platelets, purified or concentrated platelets.
  • Samples include blood or blood fractions from subjects who are thrombocytopenic and therefore have a low number of platelets in the blood or fraction.
  • the components of the test or reference samples including platelets, and detection marker-antigen complexes and components thereof may be moved relative to each other by capillary flow or diffusion through chromatographic material. The material *n
  • - 18 - may be functionalized or coated to permit, for example, cross-linking of reagents.
  • Methods for immobilizing antibodies or other binding agents to solid supports are well known in the art and are described for example in US Patent No. 4, 168, 146, Cautrecases, J. Biol. Chem. 245: 3059, 1970.
  • Materials contemplated for use herein include inorganic materials such as silica, glass, polymeric material such as cellulose, starch, dextrose, agarose, special fibrous paper (filter/chromatography paper) nitrocellulose, cellulose acetate, PVC, polyacrylamide, polysaccharide, polyacrylate, polyethylensulphonate, polyethylene and the like.
  • Chromatographically active components are simply those capable of flow through all or part of the immunochromatographic device. Chromatographic assays are particularly sophisticated and a large number of different formats are available which are tailored to the particular reagents and instruments and the outcomes required in any particular investigation. "Rapid” assays, using chromatographic principles, are tailored for accuracy, speed and ease of use. Immunoassay or enzyme- based chromatographic assays are particularly preferred and these are described in Wild D, "The Immunoassay Handbook", Nature Publishing Group, 2001 and by reference to U.S. Patent Nos.
  • control broadly includes data that the skilled person would use to facilitate the accurate interpretation of technical data.
  • a "difference" between test and reference values includes at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90%, or even an at least about 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900% or 1000% increase or decrease between values.
  • a "similarity" between test and reference values includes no more than about 20%, 18%, 16%, 14%, 12%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1 % or 0.1 % difference between values.
  • the ratio of intact:total GPlba (or total to intact GPlba) from test platelets or a test subject are compared to reference ratios(s) in one or more cohorts (populations/groups) of reference subjects whose platelet status is established (pre-determined).
  • reference subjects include normal subjects with normal platelets or thrombocytopenic subjects with functionally or proteolytically normal platelets.
  • the reference sample may be a sample from the test subject taken at an earlier time point.
  • a reference subject is a group of reference subjects.
  • the measured level or ratio in a reference subject group may be a mean value or a preselected level, threshold or range of levels or ratios that define, characterize or distinguish a particular group.
  • thresholds may be selected- that provide an acceptable ability to distinguish between platelet states.
  • a threshold or range is selected, above which (or below which) the test is considered to be "positive” and below which the test is considered to be "negative”.
  • ratio thresholds are selected to discriminate between subjects (such as between thrombocytopenic subjects) with at least about 60%, 65%, or 70% accuracy.
  • Reference herein to "derived from” means that the sample is obtained from a particular source but not necessarily directly from that source.
  • platelet proteolytic state includes proteolytic or shedding status (loss or otherwise of PMR ectodomain N-terminal to ectodomain cleavage site) which is associated with the risk or rate of platelet clearance, platelet activation or functional status (e.g., in relation to thrombus formation, thrombocytic activity, or wound healing capability).
  • the state of platelets includes an indication of the proportion of platelets having shed PMR ectodomains or the surface density of intact PMR.
  • the assay also provides and the platelet state includes an indication of the rate of receptor shedding or rate of change of receptor shedding in test platelets from a test subject, or in stored platelets.
  • detecting includes assessing the level of "intact” and “total” PMR or more particularly, the ratio of “intact” and “total” PMR by assessing the reporter signal from a detectable marker directly or indirectly attached to the "intact” PMR binding agent (antibody or fragment) or “total” PMR-binding agent (antibody or fragment thereof). Assessment may be by instrument or by visual comparison, typically with pre-determined controls.
  • detection marker or "reporter molecule”
  • detection substance a molecule or particle which, by its chemical nature, provides an analytically identifiable signal which allows the detection and quantification of antigen bound antibody detection may be qualitative or quantitative. By qualitative is meant for example, that the user may observe a similarity or difference between test and reference ratios in order to assess the outcome of the test/method.
  • Antigen binding molecules may be labeled with the same or different reporter molecules. Fluorophores are particularly useful (see Table 6). Other labels include luminescence and phosphorescence as well as infrared dyes. As will be well recognized, a wide variety of different reporter systems employing detectable molecules (substances) are available. Those allowing rapid visual detection are clearly the most useful in the context of point of care diagnostics.
  • normal is used to broadly refer to the phenotype of platelet proteolytic state that is characteristic of most of the members of the species occurring naturally. However, as thrombocytopenia caused by loss of platelet production involves platelets with substantially non-supernormal levels of proteolytic cleavage, platelets from such subjects are also considered normal and provide an example of normal platelets in accordance with the ⁇ present invention. "Supernormal” merely refers to more than normal.
  • Stratification includes identification, diagnosis, clarification, monitoring and/or determination of thrombocytopenia by evaluating the state of platelets in a subject. The process involves identifying an increased or supra normal level of platelet membrane receptor shedding or decreased platelet shedding or normal levels of platelet shedding of platelets in a test subject. Increased shedding is indicative inter alia that a subject relative to a normal subject has increased platelet clearance such as is found in immune mediated thrombocytopenia.
  • decreased shedding or improved platelet status is indicated by an increased PMR intactrtotal value which is at least 10%, 1 1%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% more than pre-treatment values.
  • subjects are monitored and treatment is maintained until the PMR. intact to total percentage value reaches at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91 % or 90%, of the level from a corresponding reference percentage from a normal control subject.
  • decreased shedding is indicated by a PMR intact:total value of that varies from a corresponding value or a low level of platelet shedding from a normal reference sample by no more than about 20, 18, 16, 14, 12, 10, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0.1%.
  • the referenced relationship value is 1 or 1 : 1 or 100%.
  • Suitable vertebrate animals that fall within the scope of the invention include, but are not restricted to, primates, livestock animals (e.g., sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g., rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g., cats, dogs) and captive wild animals (e.g., foxes, deer, dingoes) provided the subject has essentially anuclear platelets.
  • livestock animals e.g., sheep, cows, horses, donkeys, pigs
  • laboratory test animals e.g., rabbits, mice, rats, guinea pigs, hamsters
  • companion animals e.g., cats, dogs
  • the present invention contemplates the use of antigen-binding molecules that are specifically immuno-interactive with different domains of a PMR polypeptide for assessing platelet state in a test sample.
  • the antigen-binding molecule is a whole polyclonal antibody.
  • Such antibodies may be prepared, for example, by injecting the GPIb domain of interest (antigen) or peptide portions thereof into a production species, which may include mice or rabbits, to obtain polyclonal antisera. Methods of producing polyclonal antibodies are well known to those skilled in the art.
  • monoclonal antibodies may be produced using the standard method as described, for example, by Kohler and Milstein, Nature 256: 495-497, 1975, or by more recent modifications thereof as described, for example, in Coligan et ah, 1991 (supra) by immortalizing spleen or other antibody producing cells derived from a production species which has been inoculated with one or more antigens.
  • the invention also contemplates as , antigen-binding molecules Fv, Fab, Fab' and F(ab') 2 immunoglobulin fragments.
  • the antigen-binding molecule may comprise a synthetic stabilized Fv fragment.
  • Exemplary fragments of this type include single chain Fv fragments (sFv, frequently termed scFv) in which a peptide linker is used to bridge the N terminus or C terminus of a V H domain with the C terminus or N- terminus, respectively, of a V f domain.
  • sFv single chain Fv fragments
  • ScFv lack all constant parts of whole antibodies and are not able to activate complement.
  • ScFvs may be prepared, for example, in accordance with methods outlined in Kreber et ah, J.
  • the synthetic stabilized Fv fragment comprises a disulfide stabilized Fv (dsFv) in which cysteine residues are introduced into the V w and V L domains such that in the fully folded Fv molecule the two residues will form a disulfide bond between them.
  • dsFv disulfide stabilized Fv
  • Suitable methods of producing dsFv are described for example in (Glockscuther et ah Biochem.
  • Phage display and combinatorial methods for generating antigen-binding molecules are known in the art (as described in, e.g., Huse et ah, Science 246: 1275-1281 , 1989; Griffths et ah, EMBO J 12: 725-734, 1993; Hawkins et ah, J Mol Biol 226: 889- 896, 1992; Clackson et ah, Nature 352: 624-628, 1991 ; Gram et ah, PNAS 89: 3576- 3580, 1992; Garrad et al, Bio/Technology 9: 1373-1377, 1991 ; Hoogenboom et al, Nuc Acid Res 19: 4133-4137, 1991 ; and Barbas et al, PNAS 88: 7978-7982, 1991).
  • Detection of antigen binding molecules can be facilitated by coupling (e.g., physically linking) them to a detectable substance (i.e., antibody labeling).
  • detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin (a list of suitable fluorophores is provided in Table 6);
  • an example of a luminescent material includes luminol;
  • bioluminescent materials include luciferase, luciferin, and aequorin, and
  • suitable radioactive material include l25 l, , 3 I I, 35 S or 3 H.
  • the label may be selected from a group including a chromogen, a catalyst, an enzyme, a fluorophore, a chemiluminescent molecule, a lanthanide ion such as Europium (Eu 34 ), a radioisotope and a direct visual label.
  • a direct visual label use may be made, of a colloidal metallic or non-metallic particle, a dye particle, an enzyme or a substrate, an organic polymer, a latex particle, a liposome, or other vesicle containing a signal producing substance and the like.
  • Enzyme labels useful in the present invention include alkaline phosphatase, horseradish peroxidase, luciferase, ⁇ -galactosidase, glucose oxidase, lysozyme, malate dehydrogenase and the like.
  • the enzyme label may be used alone or in combination with a second enzyme in solution.
  • the proteolytic state of platelets and levels of PMR domains can be assayed using any suitable method known in the art.
  • Antibody-based techniques include immunohistological and immunohistochemical methods for measuring the level of a protein of interest in a tissue sample. Specific recognition may be provided, for example, by a primary antibody (polyclonal or monoclonal) and a secondary detection system is used to detect presence (or binding) of the primary antibody. Detectable labels can be conjugated to the secondary antibody, such as a fluorescent label, a radiolabel, or an enzyme (e.g., alkaline phosphatase, horseradish peroxidase) which produces a quantifiable, e.g., colored, product.
  • an enzyme e.g., alkaline phosphatase, horseradish peroxidase
  • the primary antibody itself can be detectably labeled.
  • immunohistological labeling of a tissue section is provided.
  • a protein extract is produced from a biological sample (e.g., tissue, cells) for analysis.
  • a biological sample e.g., tissue, cells
  • Such an extract e.g., a detergent extract
  • Such an extract can be subjected to western-blot or dot/slot assay of the level of the protein of interest, using routine immunoblotting methods (Jalkanen et al, J. Cell. Biol. 101: 976-985, 1985; Jalkanen et al., J, Cell. Biol. 105: 3087-3096, 1987).
  • antibody-based methods include immunoassays, such as the enzyme-linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA).
  • immunoassays such as the enzyme-linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA).
  • ELISA enzyme-linked immunosorbent assay
  • RIA radioimmunoassay
  • an antigen-specific monoclonal antibody can be used both as an immunoadsorbent and as an enzyme-labeled probe.
  • the amount of such protein present in a sample can be calculated by reference to the amount present in a standard preparation using a linear regression computer algorithm (see Lacobilli et al., Breast Cancer Research and Treatment 11: 19-30, 1988).
  • Flow cytometry using commercial or microfabricated flow cytometry without limitation to any particular flow cytometer and/or biosensor methods are also contemplated. Different assays have different requirements for agents, washing steps, incubation periods and the like and these are known to the skilled addressee.
  • Fluorescence based detection systems are particularly suitable for flow cytometric analysis. Other methods of analyzing fluorescence emissions are contemplated such as 2-photon and 3-photon time resolved fluorescence spectrometry, fluorescence lifetime imaging and fluorescence resonance energy transfer as known in the art. Any optical means for identifying labels may be used. Electromagnetic scattering from light and X-rays may be employed.
  • the assay is a flow cytometry based assay.
  • Flow cytometry is a powerful tool for characterizing and enumerating cells.
  • the flow cytometer detects and counts individual platelets passing in a stream through a laser beam. By examining a large number of cells, flow cytometry can provide quantitative data on the percentage of cells bearing different molecules.
  • platelets are contacted with a first binding agent that binds to the residual do main of the PMR receptor and a second binding agent that binds to the ectodomain of the PMR. These agents are conveniently labelled with different detection markers such as fluorescent or chemiluminescent dyes.
  • one or more further binding agents that bind to the receptor domain or to a binding agent directly or indirectly bound to the receptor domain may be employed.
  • the second or subsequent binding agent is typically labelled with a detection or detectable marker to facilitate evaluating the level of the two forms of the receptor (intact or cleaved) associated with test platelets in the test sample.
  • the suspended mixture of labelled cells is then forced through an aperture, creating a fine stream of liquid containing cells spaced singly at intervals.
  • each cell passes through a laser beam it scatters the laser light, and any dye molecules bound to the cell will be excited and will fluoresce.
  • Sensitive photomultiplier tubes detect both the scattered light, which gives information on the size and granularity of the cell, and the fluorescence emissions, which give information on the binding of the labelled binding agents and hence on the characteristics of each platelet in the population.
  • the data may be displayed in the form of a two-dimensional scatter diagram or as a contour diagram, where the fluorescence of one dye-labelled binding agent is plotted against that of a second, with the result that a population of cells labelling with one binding agent can be further subdivided on the basis of its reactivity with another binding agent.
  • Immunoassays are another particularly useful format of assay for the present invention.
  • a wide range of immunoassay techniques are available, such as those described in Wild D, 2001 (supra). Reference may also be made to Chapter 1 1 of Ausubel (Ed), "Current Protocols in Molecular Biology", 5 th Edition, John Wiley & Sons, Inc, NY, 2002.
  • ELISA enzyme-linked immunosorbent assay
  • RIA radio-immunoassay
  • Arrays and high throughput screening methods are also employed. These methods generally require a high level of skill in laboratory techniques.
  • a wide range of immunoassay techniques are available that providing qualitative or quantitative results. These include both single-site and two-site or “sandwich” assays of the non-competitive types, as well as in the traditional competitive binding assays. Sandwich assays are among the most useful and commonly used assays and are favored for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an antibody is immobilized on a solid or semi-solid substrate and the sample to be tested brought into contact with the bound molecule.
  • a second antibody specific to the antigen, labelled with a detection molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen- labelled antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by the detectable marker (reporter molecule).
  • the results may be qualitative or quantitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of antigen. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody.
  • a first antibody having specificity for the PMR domain antigen is either covalently or passively bound to a solid or semi-solid support.
  • the support is typically glass or a polymer, the most commonly used polymers being nitrocellulose, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride, polypropylene or mixture or derivatives of these.
  • the solid supports may be in the form of tubes, beads, discs or microplates, or any other surface suitable for conducting an immunoassay.
  • the binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing the polymer-antibody complex to the solid surface which is then washed in preparation for the test sample.
  • a bound target may be detectable by direct labelling with the antibody.
  • a second labelled antibody specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex.
  • the complex is detected by the signal emitted by the reporter molecule.
  • Biosensor devices may be employed to detect and report on antigen-antibody interactions, such as those between the ectodomain of GPIb or GPV or GPVI and an antibody or other binding agent that binds to this domain, and the residual domain of GPIba, GPV or GPVI and an antibody or antigen binding fragment or other binding agent which binds to this domain. Biosensor devices are described, for example, in U.S. Patent Publication No. 20100006452.
  • the method is a liquid phase method.
  • the sample is contacted with an agent capable of binding the antigen and a detector agent comprising a visually detectable agent such as colloidal gold or silver labelled.
  • the test sample is applied by flowing onto a defined zone of an insoluble porous support film having a pore size impassable to a complex formed between the antigen, if present, with the binding substance and the detector substance, but passable to the binding substance and detector substance while remaining uncomplexed in the absence of the desired antigen.
  • the detector substance binds with the antigen and the binding substance to form a visually inspectable complex on the surface of the porous support film.
  • the surface of the porous support is visually inspected for color to determine the presence and quantity or the absence of the antigen being assayed.
  • magnetic antibodies that bind to antigen are used to tag the antigens and a high T c superconducting quantum interference device is used to measure the amount of free and bound antibody and hence the presence or level of antigens.
  • a liposome immunomigration, liquid-phase competition strip immunoassay is, for example, described in Glorio-Paulet et al, J Agric Food Chem 48 (5): 1678-1682, 2000.
  • Biosensor devices may be employed to detect and report on antigen-antibody interactions such as those between the cytoplasmic domain of GPIb and an antibody or other binding agent that binds to this domain, and the ectodomain of GPIba and an antibody or antigen binding fragment or other binding agent which binds to this domain. Biosensor devices are described for example in US Patent Publication No. 20100006452.
  • the detection marker is a colloidal particle or microparticle.
  • Colloidal metal and metalloid particles include those comprising gold, silver, platinum, iron, copper, selenium; metal complexes such as cyclopentadienylmanganese(I) tricarbonyl, gold cluster; and microparticles such as latex and dyed latex particles.
  • the techniques used for detection of PMR domains in platelets will include internal or external standards to permit quantitative or semi-quantitative determination of those products, to thereby enable a valid comparison of the level in a biological sample with the corresponding level in a reference sample or samples.
  • standards can be determined by the skilled practitioner using standard protocols.
  • absolute values for the level of each domain can be determined by the skilled practitioner using standard protocols.
  • the present invention further provides a system where data on which ratio of intact to total PMR are provided by a client server to a central processor which analyses and compares to a control and optionally considers other information such as patient age, sex, weight and other medical conditions and then provides a report, including, for example, a platelet proteolytic state, intact:total PMR ratio or platelet maturity profile.
  • knowledge-based computer software and hardware also form part of the present invention.
  • the assays of the present invention may be used in existing or newly developed knowledge-based architecture or platforms associated with pathology services.
  • results from the assays are transmitted via a communications network (e.g. the internet) to a processing system in which an algorithm is stored and used to generate a predicted posterior probability value which translates to the index of disease probability which is then forwarded to an end user in the form of a diagnostic or predictive report.
  • the assays may, therefore, be in the form of a kit or computer-based system which comprises the reagents necessary to detect the intact to total GPIb ratio and the computer hardware and/or software to facilitate determination or determination and comparison and transmission of reports to a clinician.
  • the present invention contemplates a method of allowing a user to determine the platelet proteolytic state of a subject per se and/or with respect to thrombocytopenia, the method including receiving data in the form of a ratio of intact:total PMR ratio or other relationship value, via a communications network, the method includes conduct of the assay as described herein then transferring data from the user via a communications network; (b) processing the subject data via multivariate analysis to provide, for example, a platelet proteolytic state value; (c) determining the status of the subject in accordance with the results of the value in comparison with predetermined values; and (d) transferring an indication of the status of the subject to the user via the communications network reference to the multivariate analysis includes an algorithm which performs the multivariate or univariate analysis function.
  • the method includes, the method including receiving data in the form of a ratio of intact:total PMR ratio or other relationship value, via a communications network, the method includes conduct of the assay as described herein then transferring data from the user via a communications network.
  • the method generally further includes: (a) having the user determine the data using a remote end station; and (b) transferring the data from an end station to a base station via the communications network.
  • the base station can include first and second processing systems, in which case the method can include: (a) transferring the data to the first processing system; (b) transferring the data to the second processing system; and (c) causing the first processing system to perform the multivariate analysis function to generate the disease index value.
  • the method may also include: (a) transferring the results of the multivariate analysis function to the first processing system; and (b) causing the first processing system to determine the status of the subject.
  • the method also includes at least one of: (a) transferring the data between the communications network and the first processing system through a first firewall; and (b) transferring the data between the first and the second processing systems through a second firewall.
  • the second processing system may be coupled to a database adapted to store predetermined data and/or the multivariate analysis function, the method include: (a) querying the database to obtain at least selected predetermined data or access to the multivariate analysis function from the database; and (b) comparing the selected predetermined data to the subject data or generating a predicted probability index.
  • the second processing system can be coupled to a database, the method including storing the data in the database.
  • the method can also include having the user determine the data using a secure array, the secure array of elements capable of determining the level of lipid analytes and having a number of features each located at respective position(s) on the respective code.
  • the method typically includes causing the base station to: (a) determine the code from the data; (b) determine a layout indicating the position of each feature on the array; and (c) determine the parameter values in accordance with the determined layout, and the data.
  • the method can also include causing the base station to: (a) determine payment information, the payment information representing the provision of payment by the user; and (b) perform the comparison in response to the determination of the payment information.
  • a flow cytometry-based method has been developed for simultaneously analyzing intact/cleaved GPIba in permeabilized platelets in whole blood.
  • a rabbit polyclonal or mouse monoclonal anti-GPIba cytoplasmic domain antibodies (Green) and a rabbit polyclonal or mouse monoclonal anti-GPIba ectodomain antibody (A 2; Red) are used to assess the amount of intact receptor relative to the total amount of tail (intact plus remnant) by flow cytometry ( Figure 1).
  • dual- labeling is lised involving phycoerythrin (PE)-labeled antibody against the GPIba ectodomain
  • platelets are rapidly fixed and washed by centrifugation then permeabilized with 0.1-0.5% (w/v) saponin (ThromboFix) in buffer containing Alexa-488-labeled anti- GPIba cytoplasmic tail IgG.
  • Platelets are then washed in permeabilization buffer to remove any unbound cytoplasmic tail IgG and levels of respective antibody are assessed by flow cytometry, using the forward and side scatter characteristics of platelets and confirmed using antibodies against other platelet receptors ( ⁇ > ⁇ 3, PECAM- 1).
  • the level of Alexa-488 staining reflects the detected total amount of expressed GPIba, while levels of PE staining reflect the detected amount of the ectodomain portion of GPIba (intact GPIba).
  • the GPIba intac total ratio provides a sensitive measure of enhanced GPIb proteolysis in disease states
  • the assay described herein has been verified in platelets from 20 healthy donors and 1 1 patients with thrombocytopenia, by testing untreated platelets or platelets treated with agents known to induce proteolysis of GPIbq in permeabilized versus non- permeabilized platelets, in washed platelets versus whole blood, etc.
  • Flow cytometry data correlate with the degree of shedding assessed by Western blotting platelets from the same samples.
  • An index reporting on the normal range for GPIba molecular status has been developed from data obtained from 20 healthy donors at the Australian Centre for Blood Diseases donor database.
  • GPIba intac total ratio provides a sensitive measure of enhanced proteolysis in disease states, supported by preliminary studies in patients with thrombocytopenia
  • Table 2 shows that there was no significant correlation between GPIba intac total ratio and platelet count, GPIba surface levels or platelet volume in the Thrombocytopenia group.
  • the unknown relative contribution of platelet consumption and platelet production to thrombocytopenia is an ongoing clinical problem.
  • the present invention provides, inter alia, a new clinical tool for monitoring platelet function and survival in thrombocytopenic samples that will aid clinical decision-making in the setting of thrombocytopenia.
  • GPIba (Intact: Total) is a reliable early marker for evaluating ITP and an early marker for evaluating response to treatment
  • Platelet receptor expression and platelet parameters were assessed in patients with idiopathic thrombocytopenia (ITP) before and during steroid treatment.
  • A-IPF absolute-immature platelet fraction
  • TO thiazole orange
  • GPIba Intact:Total is independent of:
  • GPIba Intact:Total
  • GPIba Intact:Total provides an early marker for thrombocytopenia and an early marker for evaluating the response to treatment with steroid therapy or other therapies.
  • Anuclear platelets contain RNA and "reticulated” or immature platelets (reticulocytes) stain positively with thiazole orange (TO) whereas the percentage of reticulated platelets (%RP) decreases the platelets age.
  • reticulated platelets reticulocytes stain positively with thiazole orange (TO)
  • %RP percentage of reticulated platelets
  • the age of a population of platelets has been widely assessed according to the research literature using thiazole orange (TO), a membrane-permeable nucleic acid-specific fluorescent dye.
  • TO thiazole orange
  • %RP is -6% of the total platelet population, but is increased to -70% in patients with ITP, and increases to 28% during the recovery phase of chemotherapy- related thrombocytopenia.
  • GCI glycocalicin index
  • GPIba surface levels are determined.
  • GPIba surface expression decreases as normal platelets age in the circulation, and also varies with platelet count and size. Thus, changes due to disease are not distinguishable, nor can it be determined whether altered levels are due to shedding or other causes.
  • the surface expression levels will also not be sensitive to whether the cause of increased shedding is successfully treated, whereas measuring proteolytic status as determined herein is independent of platelet count and GPIba expression levels.
  • the GPIba index (Intact/total) and platelet counts were determined in subjects (Subjects C, X, V ad J) with chronic ITP before and after various treatment protocols. The results are represented graphically in Figure 4 to Figure 7. Subject C was thrombocytopenic and platelet counts gradually increased over time during steroid therapy (after one month). However, the GPIba index was approximately normal from week 1 to week 20. Subject X was non-responsive to steroids in terms of platelet counts and exhibited low platelet counts. The GPIba index level was initially low, fluctuated, but increased prior to azathioprine treatment notwithstanding decreasing platelet counts.
  • GPIba Upon treatment with azathioprine platelet levels increased and the GPIba index increased to a normal level (0.9).
  • Subject V displayed a rising GPIba index on Romiplostin.
  • an improvement in platelet quality (normalisation of the GPIba Intact:Total ratio) precedes improvement in platelet count (see Figure 7).
  • the proteolytic status of GPIba is a reliable early marker for evaluating response to treatment in ITP patients. Particularly in patients who have a low platelet count such as below 100, or about 100 x 10 6 /1.
  • Treatment with steroids Treatment with steroids (Prednisolone, Dapsone or in combination).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des dosages et des kits destinés à évaluer l'état protéolytique de plaquettes d'essai dans un échantillon biologique ou à stratifier des sujets par rapport à la thrombocytopénie, le dosage comportant les étapes consistant à détecter le niveau de récepteur membranaire de plaquettes (PMR) intact (a) et à détecter le niveau de PMR total (clivé et non clivé) (b) associé à des plaquettes de l'échantillon, et à comparer une mesure de la relation entre les niveaux (a) et (b) ("relation d'essai") à une mesure correspondante de relation dérivée d'au moins un échantillon biologique de référence ("relation de référence") choisi parmi un échantillon obtenu à partir d'un ou de plusieurs sujets de référence normaux (par ex. sains) ("relation normale de référence") ou parmi un ou plusieurs échantillons de référence présentant des niveaux mesurés prédéterminés de PMR intact et total indiquant que le sujet de référence présente des niveaux mesurés supérieurs à la normale de PMR clivé associé à des plaquettes ("relation de référence de clivage supérieur à la normale"), la similarité ou la différence entre la relation d'essai et la relation de référence indique l'état protéolytique de plaquettes dans l'échantillon d'essai. Dans un mode de réalisation, le PMR est GPIbα.
PCT/AU2012/000883 2011-07-25 2012-07-25 Dosages d'évaluation de plaquettes, diagnostic et kits associés WO2013013268A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161511463P 2011-07-25 2011-07-25
US61/511,463 2011-07-25

Publications (1)

Publication Number Publication Date
WO2013013268A1 true WO2013013268A1 (fr) 2013-01-31

Family

ID=47600394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2012/000883 WO2013013268A1 (fr) 2011-07-25 2012-07-25 Dosages d'évaluation de plaquettes, diagnostic et kits associés

Country Status (1)

Country Link
WO (1) WO2013013268A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2814398C1 (ru) * 2022-11-08 2024-02-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО УГМУ Минздрава России) Способ интегральной оценки морфофункционального статуса тромбоцитов при экспериментальных ортопедических хирургических вмешательствах

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019743A1 (en) * 2001-05-03 2005-01-27 Center For Blood Research, Inc. Compounds and methods for improving platelet recovery and function
US7645592B2 (en) * 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019743A1 (en) * 2001-05-03 2005-01-27 Center For Blood Research, Inc. Compounds and methods for improving platelet recovery and function
US7645592B2 (en) * 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AL-TAMIMI M ET AL.: "Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa.", BLOOD., vol. 117, no. 14, 7 April 2011 (2011-04-07), pages 3912 - 20 *
GARDINER EE ET AL.: "Platelet receptor shedding.", METHODS MOL BIOL., vol. 788, 2012, pages 321 - 39 *
MO X ET AL.: "Transmembrane and trans-subunit regulation of ectodomain shedding of platelet glycoprotein Ibalpha.", J BIOL CHEM., vol. 285, no. 42, 15 October 2010 (2010-10-15), pages 32096 - 104 *
QIAO J ET AL.: "Analysis of Platelet Receptor Expression in ITP.", BLOOD (ASH ANNUAL MEETING ABSTRACTS), 2011, pages 118 *
QIAO JL ET AL.: "Proteolysis of platelet receptors in humans and other species.", BIOL CHEM., vol. 391, no. 8, August 2010 (2010-08-01), pages 893 - 900 *
STIVALA S ET AL.: "Analysis of the Mechanisms of Increased Platelet Count Induced by Dietary alpha-Linolenic Acid Indicates Reduced Cleavage ofGPIb and Reduced p38 Phosphorylation.", BLOOD (ASH ANNUAL MEETING ABSTRACTS), 2011, pages 118 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2814398C1 (ru) * 2022-11-08 2024-02-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО УГМУ Минздрава России) Способ интегральной оценки морфофункционального статуса тромбоцитов при экспериментальных ортопедических хирургических вмешательствах

Similar Documents

Publication Publication Date Title
US20190049439A1 (en) Kit for a Determination Method for Calprotectin and the Use of Calprotectin as a Predictive Marker for Cardiovascular Disease
US20250258171A1 (en) Estimating cellular populations
CN105021827B (zh) 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
JP2012168012A (ja) 血管内皮障害を検査するための新規な検査方法および検査用キット
WO2012016333A1 (fr) Biomarqueurs du paludisme
EP3602070B1 (fr) Dosage fonctionnel rapide et à la demande de la thrombocytopénie induite par l'héparine
Sheng et al. Quantitative determination of agglutination based on the automatic hematology analyzer and the clinical significance of the erythrocyte-specific antibody
Yang et al. Diagnosis of paroxysmal nocturnal hemoglobinuria in peripheral blood and bone marrow with six-color flow cytometry
Kawamura et al. Development of an automated chemiluminescence enzyme immunoassay for the measurement of soluble C-type lectin-like receptor 2 (sCLEC-2) and molecular forms of sCLEC-2 measured in patient plasma
Brodard et al. Accuracy of the functional, flow cytometer-based Emo-Test HIT Confirm® for the diagnosis of heparin-induced thrombocytopenia
WO2013013268A1 (fr) Dosages d'évaluation de plaquettes, diagnostic et kits associés
US12265084B2 (en) Method for analyzing the platelets of a blood sample
Courcelles et al. Characterisation of an interference affecting the triiodothyronine measurement on two different immunoassays
US20250130237A1 (en) Point of Care Assays
AU2011215826A1 (en) Compositions and methods for predicting cardiovascular events
US20100120080A1 (en) Cancer diagnosis using ki-67
Villamor ZAP‐70 Staining in Chronic Lymphocytic Leukemia
Kang SeonJoo et al. Comparison of ABO antibody titers on the basis of the antibody detection method used.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12817881

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12817881

Country of ref document: EP

Kind code of ref document: A1